Harry Finch

This inventor holds 6 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 1 EPO patent. Top assignees: Cancer Research Technology Limited, The Institute of Cancer Research, Vernalis &r&d) Ltd.. Active years: 2010-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Harry Finch. Retrieved from https://idiyas.com/inventor/harry-finch-1s3m0rr2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 1)

% Patents Active = 50.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 1

Average Co-Inventor Count = 8.0

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Abington, GB (2010 - 2017)
Great Abington, GB (2019 - 2022)

Company Filing History:

6 out of 269

Cancer Research Technology Limited

patents

6 out of 24

The Institute of Cancer Research

Vernalis (Cambridge) Limited

patents

where one patent can have more than one assignee

Years Active: 2010-2022

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11234987 - Isoxazole compounds as inhibitors of heat shock proteins (2022-02-01),

2. 10413550 - Isoxazole compounds as inhibitors of heat shock proteins (2019-09-17),

3. 9718793 - Isoxazole compounds as inhibitors of heat shock proteins (2017-08-01),

4. 8507480 - Isoxazole compounds as inhibitors of heat shock proteins (2013-08-13),

5. 8450310 - Isoxazole compounds as inhibitors of heat shock proteins (2013-05-28),

6. 7705027 - Isoxazole compounds as inhibitors of heat shock proteins (2010-04-27),

Title: Innovations of Harry Finch in Cancer Research

Introduction

Harry Finch is a notable inventor based in Abington, GB, recognized for his contributions to the field of cancer research. He holds a total of six patents, showcasing his innovative approach to developing treatments for various diseases, particularly cancers.

Latest Patents

Among his latest patents is a significant invention involving isoxazole compounds as inhibitors of heat shock proteins. These compounds are designed to inhibit HSP90 activity, which is crucial in the treatment of cancers. The isoxazoles are characterized by specific chemical formulas that include various substituents, making them versatile in their application for cancer therapies.

Career Highlights

Throughout his career, Harry Finch has made substantial contributions to cancer research. He has worked with prominent organizations such as Cancer Research Technology Limited and the Institute of Cancer Research, where he has furthered his research and development efforts.

Collaborations

Harry Finch has collaborated with notable colleagues in the field, including Martin James Drysdale and Brian William Dymock. These collaborations have enhanced his research capabilities and contributed to the advancement of cancer treatment methodologies.

Conclusion

Harry Finch's innovative work in developing isoxazole compounds and his collaborations with esteemed colleagues highlight his significant impact on cancer research. His contributions continue to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.